Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine determine the maximum tolerated dose (MTD) and
safety of the combination of Chidamide combined with CHOEP(cyclophosphamide，
epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in
newly-diagnosed T-NHL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Beijing Cancer Hospital Chinese PLA General Hospital Peking University First Hospital Peking University Third Hospital Tianjin Medical University Cancer Institute and Hospital